SCHEMBL5608005

SCHEMBL5608005

CC(=O)NC12CC3CC(CC(O)(C3)C1)C2

nearest known ligand 0.51

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.47
EPHX1 P07099 2/20 0.47
ALDH1A1 P00352 1/20 0.46
EPHX2 P34913 4/20 0.44
MDH1 P40925 1/20 0.43
MDH2 P40926 1/20 0.43
DPP4 P27487 3/20 0.43
DPP7 Q9UHL4 1/20 0.42
CNR1 P21554 2/20 0.42
CNR2 P34972 2/20 0.42
PKM P14618 1/20 0.41
GAA P10253 1/20 0.41
KMT2A Q03164 1/20 0.41
RXFP1 Q9HBX9 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29602546 1.00 TSHR (0.47) TSHREPHX1ALDH1A1EPHX2MDH1
SCHEMBL6058547 0.88 EPHX1 (0.53) TSHREPHX1ALDH1A1EPHX2GAA
SCHEMBL2851919 0.83 ALDH1A1 (0.47) TSHREPHX1ALDH1A1EPHX2MDH1
SCHEMBL5608356 0.83 EPHX1 (0.44) TSHREPHX1ALDH1A1EPHX2MDH1
SCHEMBL7636763 0.83 EPHX1 (0.44) TSHREPHX1ALDH1A1EPHX2MDH1
SCHEMBL12783362 0.83 TSHR (0.43) TSHREPHX1ALDH1A1EPHX2MDH1
SCHEMBL5608094 0.82 ALDH1A1 (0.47) TSHREPHX1ALDH1A1EPHX2MDH1
SCHEMBL6531345 0.81 ALDH1A1 (0.46) TSHREPHX1ALDH1A1EPHX2MDH1
SCHEMBL31144035 0.81 ALDH1A1 (0.46) TSHREPHX1ALDH1A1EPHX2MDH1
SCHEMBL4975642 0.81 TSHR (0.70) TSHREPHX1EPHX2GAAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116789600-A Preparation method and application of novel tetrahydroindazole antitumor compound 深圳市人民医院 2023-09-22 CN claimed
CN-112250594-B Method for preparing 3-acetamido-1-adamantanol 浙江荣耀生物科技股份有限公司 2023-09-12 CN claimed
CN-112694410-A 3-amino-1-adamantanol and synthesis method thereof 广东仁康达材料科技有限公司 2021-04-23 CN claimed
CN-112250594-A Method for preparing 3-acetamido-1-adamantanol 浙江荣耀生物科技股份有限公司 2021-01-22 CN claimed
JP-11106360-A None JP disclosed
CN-116444438-B Benzamide compound and preparation method, using method and application thereof 深圳市人民医院 2024-02-13 CN disclosed
CN-116924918-B Preparation method of 3-amino-1-adamantanol 浙江荣耀生物科技股份有限公司 2024-02-09 CN disclosed
CN-116924918-A Preparation method of 3-amino-1-adamantanol 浙江荣耀生物科技股份有限公司 2023-10-24 CN disclosed
CN-116789600-A Preparation method and application of novel tetrahydroindazole antitumor compound 深圳市人民医院 2023-09-22 CN disclosed
CN-112250594-B Method for preparing 3-acetamido-1-adamantanol 浙江荣耀生物科技股份有限公司 2023-09-12 CN disclosed
CN-112250594-B Method for preparing 3-acetamido-1-adamantanol 浙江荣耀生物科技股份有限公司 2023-09-12 CN disclosed
CN-112250594-B Method for preparing 3-acetamido-1-adamantanol 浙江荣耀生物科技股份有限公司 2023-09-12 CN disclosed
US-20080318922-A1 Bicyclic Pyrrole Derivatives DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2008-12-25 US disclosed
US-RE39744-E1 Adamantane derivatives and process for producing them DAICEL CHEMICAL INDUSTRIES, LTD. (JP) 2007-07-24 US disclosed
EP-0915077-B1 POLYMERIZABLE ADAMANTANE DERIVATIVES AND PROCESS FOR PRODUCING THE SAME DAICEL CHEM (JP) 2004-11-17 EP disclosed
US-6392104-B1 CHEMICAL INTERMEDIATES FOR DRUGS, AGRICULTURE DAICEL CHEMICAL INDUSTRIES, LTD. (JP) 2002-05-21 US disclosed
US-6235851-B1 ESTERIFICATION OR AMIDATION REACTION OF AN ADAMANTANE DERIVATIVE; GROUP 3A METAL CATALYST DAICEL CHEMICAL INDUSTRIES, LTD. (JP) 2001-05-22 US disclosed
EP-0927711-A1 ADAMANTANE DERIVATIVES AND PROCESS FOR PRODUCING THEM Daicel Chemical Industries, Ltd. (JP) 1999-07-07 EP disclosed
EP-0915077-A1 POLYMERIZABLE ADAMANTANE DERIVATIVES AND PROCESS FOR PRODUCING THE SAME Daicel Chemical Industries, Ltd. (JP) 1999-05-12 EP disclosed
JP-H11106360-A ADAMANTANE DERIVATIVE AND ITS PRODUCTION DAICEL CHEM IND LTD 1999-04-20 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080318922-A1 Bicyclic Pyrrole Derivatives DPP4, DPP7, DPP3 TSHR 451/4885EPHX1 4094/4885ALDH1A1 62/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.